Michel Feletou Selected Research

capadenoson

1/2021

Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michel Feletou Research Topics

Disease

3	Hypertension (High Blood Pressure) 03/2006 - 02/2002
1	Bradycardia 01/2021
1	Heart Failure 01/2021
1	Stroke (Strokes) 03/2006

Drug/Important Bio-Agent (IBA)

1	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	Adenosine A1 ReceptorIBA 01/2021
1	Adenosine-5'-(N-ethylcarboxamide) (NECA)IBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	capadenosonIBA 01/2021
1	VCP746IBA 01/2021
1	PotassiumIBA 03/2006
1	SaltsIBA 03/2006
1	Sodium Chloride FDA LinkGeneric 03/2006
1	Thromboxane Receptors (Thromboxane Receptor)IBA 02/2005
1	Vasodilator Agents (Vasodilators)IBA 02/2002
1	Hydralazine (Apresoline)FDA LinkGeneric 02/2002
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 02/2002
1	EnzymesIBA 02/2002